Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban or rivaroxaban versus aspirin for primary prevention of thromboembolic complications in JAK2V617F-positive myeloproliferative neoplasms
2024-515362-13-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- Aug 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of apixaban, rivaroxaban and aspirin in polycythemia vera (PV), thrombocythemia, primary myelofibrosis (PMF) and 1 more (2 arms), sponsored by Centre Hospitalier Universitaire de Brest. Primary endpoint: Time to occurrence of arterial or venous thromboembolic events. Planned start Aug 2024; status: authorised.
02
Drugs
apixabanrivaroxabanaspirin
03
Conditions
polycythemia vera (PV)thrombocythemiaprimary myelofibrosis (PMF)Philadelphia-negative myeloproliferative neoplasm
Beyond the preview
Go deeper on 2024-515362-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515362-13-00.